Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes
Primary Purpose
Diabetes, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
biphasic insulin aspart 30
metformin
biphasic insulin aspart 50
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes
- Currently treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months
- HbA1c (Glycosylated Haemoglobin A1c) between 7.5% - 12.0% (both inclusive)
- FPG (Fasting Plasma Glucose) higher than 7.0 mmol/L
- BMI (Body Mass Index) 23-40 kg/sq.m (both inclusive)
Exclusion Criteria:
- Metformin contraindications according to local practice
- Systemic use of TZDs (thiazolidinediones) for more than 1 month within 6 months prior to this trial
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
BIAsp 50-50-30
BIAsp 30-30
Arm Description
Biphasic insulin aspart 50 administered before breakfast and lunch + biphasic insulin aspart 30 at dinner combined with metformin
Biphasic insulin aspart 30 administered before breakfast and dinner combined with metformin
Outcomes
Primary Outcome Measures
Change in Glycosylated Haemoglobin A1c (HbA1c)
Change in glycosylated haemoglobin A1c (HbA1c) from week 0 (baseline) to end of treatment (week 16)
Secondary Outcome Measures
The Percentage of Subjects Achieving HbA1c Treatment Targets
The percentage of subjects who after 16 weeks of treatment met the glycosylated haemoglobin A1c (HbA1c) treatment targets below 7%, or below or equal to 6.5%.
Change and Daily Average in 8-point Plasma Glucose
Change in 8-point plasma glucose from baseline (week 0) to at end of treatment (week 16). 8-point plasma glucose was measured at following time points: Before each meal, 120 minutes after the start of each meal, at bedtime, and at 3:00 AM in the morning. Daily average was calculated at the end of treatment.
Change and Daily Average in Prandial Plasma Glucose Increment
Change in prandial (mealtime) plasma glucose increment from baseline (week 0) to end of treatment (week 16). Daily average prandial plasma glucose increment was calculated at end of treatment.
The Total Increase in Total Daily Insulin Dose Per Body Weight
The total increase in total daily insulin dose per body weight from baseline (week 0) to end of treatment (week 16).
Change in Body Weight
Change in body weight from baseline (week 0) to end of treatment (week 16)
Number of Hypoglycaemic Episodes
Number of hypoglycaemic episodes occurring after baseline (week 0) to the end of treatment (week 16) in each treatment group. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL.
Number of Nocturnal Hypoglycaemic Episodes
Number of nocturnal hypoglycaemic episodes occurring after baseline (week 0) to end of treatment (week 16) in each treatment group. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00627445
Brief Title
Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes
Official Title
Effect of Biphasic Insulin Aspart 50 Compared to Biphasic Insulin Aspart 30 Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
February 2008 (undefined)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
January 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is conducted in Asia. The trial aims to investigate if the blood glucose control of biphasic insulin aspart 50 is at least as effective as treatment with biphasic insulin aspart 30 both in combination with metformin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
441 (Actual)
8. Arms, Groups, and Interventions
Arm Title
BIAsp 50-50-30
Arm Type
Experimental
Arm Description
Biphasic insulin aspart 50 administered before breakfast and lunch + biphasic insulin aspart 30 at dinner combined with metformin
Arm Title
BIAsp 30-30
Arm Type
Active Comparator
Arm Description
Biphasic insulin aspart 30 administered before breakfast and dinner combined with metformin
Intervention Type
Drug
Intervention Name(s)
biphasic insulin aspart 30
Intervention Description
Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
Intervention Type
Drug
Intervention Name(s)
metformin
Intervention Description
Tablets, 500 - 2000 mg, once, twice or three times daily
Intervention Type
Drug
Intervention Name(s)
biphasic insulin aspart 50
Intervention Description
Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
Primary Outcome Measure Information:
Title
Change in Glycosylated Haemoglobin A1c (HbA1c)
Description
Change in glycosylated haemoglobin A1c (HbA1c) from week 0 (baseline) to end of treatment (week 16)
Time Frame
week 0, week 16
Secondary Outcome Measure Information:
Title
The Percentage of Subjects Achieving HbA1c Treatment Targets
Description
The percentage of subjects who after 16 weeks of treatment met the glycosylated haemoglobin A1c (HbA1c) treatment targets below 7%, or below or equal to 6.5%.
Time Frame
week 16
Title
Change and Daily Average in 8-point Plasma Glucose
Description
Change in 8-point plasma glucose from baseline (week 0) to at end of treatment (week 16). 8-point plasma glucose was measured at following time points: Before each meal, 120 minutes after the start of each meal, at bedtime, and at 3:00 AM in the morning. Daily average was calculated at the end of treatment.
Time Frame
week 0, week 16
Title
Change and Daily Average in Prandial Plasma Glucose Increment
Description
Change in prandial (mealtime) plasma glucose increment from baseline (week 0) to end of treatment (week 16). Daily average prandial plasma glucose increment was calculated at end of treatment.
Time Frame
week 0, week 16
Title
The Total Increase in Total Daily Insulin Dose Per Body Weight
Description
The total increase in total daily insulin dose per body weight from baseline (week 0) to end of treatment (week 16).
Time Frame
week 0, week 16
Title
Change in Body Weight
Description
Change in body weight from baseline (week 0) to end of treatment (week 16)
Time Frame
week 0, week 16
Title
Number of Hypoglycaemic Episodes
Description
Number of hypoglycaemic episodes occurring after baseline (week 0) to the end of treatment (week 16) in each treatment group. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL.
Time Frame
weeks 0-16
Title
Number of Nocturnal Hypoglycaemic Episodes
Description
Number of nocturnal hypoglycaemic episodes occurring after baseline (week 0) to end of treatment (week 16) in each treatment group. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L or 56 mg/dL. Symptoms only if subject was able to treat her/himself and with either no plasma glucose or blood glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L or 56 mg/dL.
Time Frame
weeks 0-16
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes
Currently treated with premix human insulin twice daily with or without oral antidiabetic drugs for at least 3 months
HbA1c (Glycosylated Haemoglobin A1c) between 7.5% - 12.0% (both inclusive)
FPG (Fasting Plasma Glucose) higher than 7.0 mmol/L
BMI (Body Mass Index) 23-40 kg/sq.m (both inclusive)
Exclusion Criteria:
Metformin contraindications according to local practice
Systemic use of TZDs (thiazolidinediones) for more than 1 month within 6 months prior to this trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100034
Country
China
12. IPD Sharing Statement
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk
Learn more about this trial
Effect of Biphasic Insulin Aspart 50 on Blood Glucose Control in Subjects With Type 2 Diabetes
We'll reach out to this number within 24 hrs